gemfibrozil vs repaglinide
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of gemfibrozil and repaglinide. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
major Known Drug Interaction
Table 3: Clinically Important Drug Interactions with Repaglinide Gemfibrozil Clinical Impact: Gemfibrozil significantly increased repaglinide exposures by 8.1 fold [see Clinical Pharmacology (12.3) ] Intervention: Do not administer repaglinide to patients receiving gemfibrozil [see Contraindications (4) ] . Clopidogrel Clinical Impact: Clopidogrel increased repaglinide exposures by 3.9 to 5.1 fold [see Clinical Pharmacology (12.3) ] Intervention: Avoid concomitant use of repaglinide with clopidogrel. Drugs that are known to inhibit CYP2C8 include trimethoprim, gemfibrozil, montelukast,...
Lopid
Prandin
Gemfibrozil is a medicine that helps lower high triglyceride levels in your blood. It can also help reduce the risk of heart disease in some people.
Repaglinide (Prandin) helps control blood sugar in adults with type 2 diabetes. It works best when used with diet and exercise.
This medicine is used to treat very high triglyceride levels in adults when diet alone doesn't work. High triglycerides can increase your risk of pancreatitis. Gemfibrozil can also lower the risk of heart disease in some people with specific cholesterol problems.
Repaglinide is used to lower blood sugar in adults with type 2 diabetes. It should be used along with a healthy diet and regular exercise. This medicine is not for people with type 1 diabetes or diabetic ketoacidosis.
Gemfibrozil belongs to a class of drugs called fibrates. It works by decreasing the amount of triglycerides your body makes. It also helps to increase HDL (good) cholesterol.
Repaglinide helps your pancreas release insulin after you eat. Insulin helps move sugar from your blood into your cells. This lowers your blood sugar levels.
- • Upset stomach
- • Indigestion
- • Abdominal pain
- • Low blood sugar
- • Upper respiratory infection
- • Headache
- • Sinus infection
- • Joint pain
- Nausea 883
- Fatigue 825
- Diarrhoea 726
- Pain 693
- Dizziness 617
- Hypoglycaemia 765
- Acute Kidney Injury 548
- Drug Interaction 418
- Diarrhoea 365
- Lactic Acidosis 364
This medicine may increase your risk of gallbladder problems, including the need for surgery. Before taking gemfibrozil, tell your doctor if you have liver or kidney problems. You should not take this medicine with simvastatin, repaglinide, dasabuvir, or selexipag.
Repaglinide can cause low blood sugar (hypoglycemia). If you skip a meal, skip your dose of repaglinide to avoid low blood sugar. Do not use repaglinide with NPH-insulin. There is no proof that repaglinide lowers your risk of heart problems.
Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. It is not known if gemfibrozil can harm your unborn baby. It is also not known if gemfibrozil passes into breast milk.
Tell your doctor if you are pregnant or plan to become pregnant. Poorly controlled diabetes during pregnancy can harm both the mother and the baby. Repaglinide is not recommended while breastfeeding due to the risk of low blood sugar in the baby.
Also Compare, Nearby Drugs
Compare gemfibrozil with
Compare repaglinide with
How to Read This gemfibrozil vs repaglinide Comparison
gemfibrozil is classified in the Fibrate drug class, while repaglinide sits within the Meglitinide class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, gemfibrozil has 3,744 submissions while repaglinide has 2,460. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known major interaction flagged in FDA labeling, attributed to gemfibrozil stops your body from getting rid of repaglinide, which causes the level of repaglinide in your blood to become dangerously high.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for gemfibrozil or repaglinide.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.